Prothena Corporation

Prothena Corporation

Prothena emerged in 2012 as a spin-out from Elan Pharmaceuticals, inheriting a protein immunotherapy platform aimed at diseases caused by misfolded proteins. The company has remained focused exclusively on neurodegenerative and rare peripheral amyloid conditions, with its lead candidate, birtamimab, targeting AL amyloidosis — a buildup of abnormal antibody light chains that progressively destroys organ function. A pivotal Phase 3 trial readout expected in 2025 could define the company's trajectory. The founding thesis carries through: protein clearance can alter disease course. The firm's portfolio also includes prasinezumab, a Parkinson's disease antibody partnered with Roche, and a preclinical tau program for Alzheimer's spearheaded with Bristol Myers Squibb under a 2021 deal that brought in $80 million upfront. Prothena retains full rights to its AL and ATTR amyloidosis programs, while neurodegenerative blockbusters are co-developed with large pharma to share the enormous trial costs. The pipeline splits cleanly between wholly owned rare-disease assets and partnered neurodegeneration programs, with cash runway projected into mid-2027 based on current burn rates (per the firm, Q1 2025 earnings call, May 2025). Prothena operates with roughly 145 employees across Dublin and South San Francisco, maintaining a lean discovery engine supported by outsized pharma partnerships. The balance sheet held $626.4 million in cash and equivalents at year-end 2024, with no outstanding debt — an unusual capital structure for a pre-revenue biotech (per company 10-K, 2024). CEO Chad Swanson, formerly the Chief Development Officer, was promoted in September 2024 following Gene Kinney's retirement, signaling a clinical execution mandate as the firm approaches its most consequential data readout. The company is publicly listed on Nasdaq under the ticker PRTA. What distinguishes Prothena is its persistent focus on the mechanistic root of disease rather than chasing symptomatic treatments. The dual-track model — wholly owned rare-disease programs funded by pharma partnerships in larger neurodegeneration markets — functions as a portfolio hedging strategy rarely seen outside the oncology space. No founder dynasty is present; governance is institutional, with a board stacked with clinical and financial veterans of the biotech spinout cycle.